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ABSTRACT 
BACKGROUND AND AIMS. Drug development has been classically associated with large 
pharmaceutical companies developing ‘blockbuster’ drugs aimed at large patient populations through 
high market penetration and multiple indication life cycle management. Higher costs and lower output 
have rendered this model inefficient and unsustainable. The aims of this thesis were to assess: 
suitability of test procedures, benefit to risk profile during development, importance of stages of 
discovery and development for benefit/risk and entrepreneurship, expert judgement in making ‘go/no-
go’ decisions, and implications for innovation.
METHODS. Literature review was used to identify why drugs fail and characterise drug regulation 
history. Examples of drugs in different development stages were critically reviewed for choice of test 
procedure and assessment of benefit/risk in context with knowledge and scientific expertise today. An 
18-step model of drug discovery and development was defined. Using web-based questionnaires, 
health experts were asked the importance of each step for assessing benefit/risk, and entrepreneurial 
input. Individual judgement using real drug case scenarios was studied by scoring ‘go/no-go’ 
decisions on a Likert scale. Relative importance of assessment of risk versus entrepreneurial need was 
compared on the model. Influence of entrepreneurial characteristics on the expert assessments and on 
decision making was explored.
RESULTS. Drugs failed development for inefficacy and toxicity. Choice of test procedure confirmed 
anti-hypertensive and anti-asthmatic efficacy of K+ channel openers in the laboratory, but these 
models were poor predictors of clinical potential. Alternative indications and potential routes of 
administration were left unexplored. Advances in molecular biology and screening have still failed to 
yield a product with full clinical potential. Retrospective case studies and prospective multicentre 
studies for an approved immunosuppressant proved valuable approaches for assessing risk of 
malignancy and risk during pregnancy. Identifying risk factors helps patients and carers in counselling 
to reach better outcomes. Health experts perceived toxicology, clinical trials, and pharmacovigilance 
most important for benefit/risk assessment. In contrast, drug discovery and later phases of 
development were of entrepreneurial importance. Results modelling revealed in-house entrepreneurial 
‘core’ and external outsourcing opportunity. Experts showed marked variability in individual 
judgment for making ‘go/no-go’ decisions despite having the same information. Expert risk 
perception and decision making were not consistently influenced by entrepreneurial character. 
Optimised decision making was identified to be critical for effective drug development. 
CONCLUSIONS. These findings reinforce the opinion that restructuring and opening up drug 
discovery and development to more external input is likely to increase the innovative capacity and 
efficiency of the whole drug discovery and development process.
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